Type 2 Diabetes Clinical Trials Near You

Type 2 diabetes trials in 2026 reflect the paradigm shift from simply controlling blood sugar toward treating diabetes as a multi-system metabolic disease. GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) have demonstrated weight loss of 15–22%, cardiovascular event reduction, kidney protection, and liver fat improvement alongside glucose control. Trials are testing triple-target agonists hitting GLP-1, GIP, and glucagon receptors simultaneously.

Oral formulations represent a major convenience advance. Oral semaglutide and the non-peptide oral GLP-1 agonist orforglipron are in late-stage trials to replace weekly injections with daily pills, potentially transforming adherence in a disease where medication compliance is a persistent challenge.

SGLT2 inhibitors (empagliflozin, dapagliflozin) continue expanding their role, with trials demonstrating kidney protection in diabetic kidney disease and heart failure benefit — establishing them as cardiorenal medications that happen to also lower glucose.

Precision medicine approaches are gaining traction: trials stratify patients by genetic risk scores, residual beta-cell function, and insulin resistance patterns to match individuals with the therapy most likely to benefit them personally.

For insulin-dependent type 2 diabetes, islet cell transplantation and stem cell-derived beta-cell replacement therapies are in Phase 1–2 trials, aiming to restore natural insulin production.

Patient considerations: Diabetes trials often require a stable medication regimen for 8–12 weeks before enrollment. Expect frequent blood glucose monitoring (some trials provide continuous glucose monitors) and regular HbA1c tests. Many trials accept patients taking multiple diabetes medications including insulin — you generally don't need to stop current treatment to participate.